Lilly, Novo expand DTC reach of obesity meds after compound win

Eli Lilly and Novo Nordisk have scored big wins from the FDA in recent months, as the agency cracks down on copycat versions of their GLP-1 blockbusters. Now, as the battle with compound GLP-1s comes to an end, both pharma giants are ramping up their direct-to-consumer offerings in the obesity space.